Monograph
C09AA03 - Lisinopril |
Not porphyrinogenic |
NP |
Rationale
Not metabolised. Some clinical experience as well as two references point to non-porphyrinogenicity.
Risk for gastrointestinal adverse events in the form of diarrhoea and vomiting motivates vigilance against insufficient intake of food, especially of carbohydrate.
Chemical description
ACE-inhibitor. Excreted in unchanged form in urine. Thunell, patient reports (n=4): tolerated. Andersson, patient reports (n=7): tolerated. Used in Swedish porphyria ward. French list: safe. South African list: use with care.
Therapeutic characteristics
Common side effects that can be potentially porphyrinogenic through reduction in carbohydrate intake and that also can be confused with an acute porphyria attack are diarrhoea and vomiting.
IPNet drug reports
Uneventful use reported in 26 patients with acute porphyria.
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Finland
Latvia
Serbia
